Sanofi’s Lemtrada Suffers Setback In Key U.S. Market

02.01.2014 - Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug that was at the heart of the French drugmaker's $20...